C3 mutations and poor pegcetacoplan response in paroxysmal nocturnal hemoglobinuria
Santiago Rodríguez de Córdoba, Andrea Reparaz Suevos, Silvia González Sanz, Francisco J. Fernández, M. Cristina Vega, Enrique Colado Varela, Alejandro Lada Colunga, Juan Carlos Vallejo Llamas, Ana Pilar Gonzalez-Rodríguez · 2025
Read C3 mutations and poor pegcetacoplan response in paroxysmal nocturnal hemoglobinuria by Santiago Rodríguez de Córdoba, Andrea Reparaz Suevos, Silvia González Sanz, Francisco J. Fernández, M. Cristina Vega, Enrique Colado Varela, Alejandro Lada Colunga, Juan Carlos Vallejo Llamas, Ana Pilar Gonzalez-Rodríguez (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12689931.txt.
Description
IntroductionParoxysmal nocturnal hemoglobinuria (PNH) is treated with complement inhibitors, yet incomplete responses remain a challenge. Terminal inhibition with eculizumab prevents intravascular hemolysis but often leaves residual extravascular hemolysis, while proximal inhibitors such as pegcetacoplan mitigate extravascular hemolysis though intravascular hemolysis may persist. Understanding resistance mechanisms is critical to guide therapy.
Catalog record
| CREATOR | Santiago Rodríguez de Córdoba, Andrea Reparaz Suevos, Silvia González Sanz, Francisco J. Fernández, M. Cristina Vega, Enrique Colado Varela, Alejandro Lada Colunga, Juan Carlos Vallejo Llamas, Ana Pilar Gonzalez-Rodríguez |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |